MedTrace Logo

Ulinastatin Improves Post-Cardiac Surgery Cognitive Dysfunction

NCT06268249 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 7065

Last updated 2024-10-16

No results posted yet for this study

Summary

The study comprised two primary components: a retrospective analysis of clinical big data and a conventional prospective cohort study involving patients undergoing cardiac surgery. The objectives were: 1. To assess the preventive effect of ursodeoxycholic acid on post-cardiac surgery cognitive dysfunction over an eight-year period. 2. To analyze preoperative and postoperative 24-hour plasma samples from prior studies to quantify the levels of glycocalyx and its associated regulatory factors. 3. To evaluate the clinical association between the measured parameters and patient outcomes.

Conditions

  • Postoperative Cognitive Dysfunction
  • Postoperative Delirium

Interventions

DRUG

Ulinastatin

Ulinastatin was pumped continuously during the operation

Sponsors & Collaborators

  • Qin Zhang

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-01-01
Primary Completion
2022-12-30
Completion
2023-12-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06268249 on ClinicalTrials.gov